Pola-R-CHP for High-Risk DLBCL: A Real Benefit That Isn't Quite the Whole Story
The trial that changed first-line treatment for higher-risk DLBCL showed a real gain in progression-free survival. It did not show a survival gain that reached statistical significance — and both facts have to be said out loud to counsel her honestly.
Diane S. has run her high school through two accreditation reviews without missing a single day of work, a fact she mentions not as a boast but as context for why she told her oncology team, in almost the same breath as her diagnosis, that she intends to keep working through treatment if the schedule allows it. She is 58, and was found to have diffuse large B-cell lymphoma after a persistent, painless neck mass prompted biopsy during what she'd assumed was a routine sinus infection workup.
Pathology confirmed non-GCB, activated-B-cell-like DLBCL, and staging placed her International Prognostic Index score at 3 — high-intermediate risk, the exact territory where the choice of first-line regimen has become a genuinely active, current question in the field over the past few years. She is otherwise fit, with no cardiac or other comorbidity that would limit which regimen is even on the table.
POLARIX, the trial that established polatuzumab vedotin added to R-CHP (replacing vincristine) as a first-line option, found a real progression-free survival benefit over standard R-CHOP concentrated most clearly in higher-IPI patients — a population her own score places her in directly. What that trial did not show, and what has to be said to her as plainly as the benefit itself, is that the overall survival difference between arms did not reach statistical significance. A real gain in one endpoint and an unconfirmed gain in the other are not the same finding, even when they come from the same trial and the same patients, and she has said clearly that she wants the distinction explained to her directly rather than smoothed over.
A real benefit, and the endpoint it didn't reach
Given her IPI of 3, I'd recommend pola-R-CHP. POLARIX, Tilly et al., 2022, showed a real progression-free survival benefit over standard R-CHOP, concentrated most clearly in higher-IPI patients — exactly her risk category. It's now a guideline-preferred option for first-line higher-risk DLBCL.
I want to be precise about what POLARIX actually showed, because the PFS result and the OS result are not the same claim. The overall survival difference between arms did not reach statistical significance. R-CHOP remains a well-established, effective, and far less costly regimen. Given that the survival benefit itself is unconfirmed, I don't think we should present pola-R-CHP to her as an obviously superior standard — cost and her own preference deserve real weight in a decision this close.
You're right that the OS difference wasn't statistically significant — I'd characterize that exactly the way you did.
But her diagnosis isn't just 'high-IPI DLBCL' in the abstract — it's specifically non-GCB, activated-B-cell-like disease. POLARIX's own subgroup analyses suggested the PFS benefit may be more pronounced in exactly that subtype, though I'll say plainly that's a hypothesis-generating subgroup finding, not a confirmed, powered result. Combined with her IPI score, that molecular-subtype enrichment tips the balance toward pola-R-CHP more confidently for her specifically than the IPI number alone would justify.
Agreed: proceed with pola-R-CHP given her combination of elevated IPI and non-GCB subtype. She was counseled explicitly and in plain terms that the regimen's overall survival benefit remains statistically unconfirmed despite a real progression-free survival gain, and that R-CHOP remained a reasonable, well-established alternative she could have chosen instead. She confirmed she understood the distinction and wanted to proceed with pola-R-CHP.